Episodes

  • Using OCT Angiography to Distinguish RVO and RAO

    Using OCT Angiography to Distinguish RVO and RAO
    Jan 9 2025
    How can OCT angiography help retina specialists distinguish between retinal vein occlusion (RVO) and retinal artery occlusion (RAO) in patients who present without acute findings? Using real-world cases as a backdrop, Yasha Modi, MD, and Kat Talcott, MD, discuss Dr. Modi’s approach to distinguishing RVO and RAO via OCT angiography and review which specific OCT angiography findings may indicate referral to cardiology. Later in the episode, they explore the utility and limitations of OCT angiography in patients with diabetic retinopathy. This episode is supported by Zeiss Professional Education.
    Show more Show less
    18 mins
  • OCT Angiography in a Real-world CSR Case

    OCT Angiography in a Real-world CSR Case
    Jan 9 2025
    What role can OCT angiography play in tracking the development of central serous retinopathy (CSR)? Yasha Modi, MD, and Kat Talcott, MD, review the use of OCT angiography in a real-world CSR case, discuss the value of selecting OCT angiography over fluorescein angiography for patients with neovascularization, and parse which populations are not a good fit for OCT angiography. This episode is supported by Zeiss Professional Education.
    Show more Show less
    18 mins
  • Switching from Aflibercept to Faricimab in Wet AMD Patients

    Switching from Aflibercept to Faricimab in Wet AMD Patients
    Dec 19 2024
    Does switching wet AMD patients from aflibercept (Eylea, Regeneron) to faricimab (Vabysmo, Genentech) improve disease outcomes? Join Ben Young, MD, MS, and his guests Lediana Goduni, MD, and Joshua Uhr, MD, as they explore this a recent peer review paper on this question. What are the potential benefits of such a switch? How should providers use findings such as these to inform their practice? And are significant improvements in anatomy relevant if vision gains are unchanged?
    Show more Show less
    22 mins
  • GA Options in Clinical Therapy: Which Patients Are a Fit for GA Treatment?

    GA Options in Clinical Therapy: Which Patients Are a Fit for GA Treatment?
    Dec 12 2024
    What are the benefits and limitations to FDA-approved therapies for geographic atrophy? John Kitchens, MD, is joined by Saradha Chexal, MD, and Geeta Lalwani, MD, as they explore which patients are best suited for treatment, how best to succinctly set expectations for outcomes, and whether patients on GA therapy may also be well-suited AREDS vitamins.
    Show more Show less
    17 mins
  • AAO '24: Real-world PDR Treatment vs. Protocol S Guidelines, and Retinal Imaging for Alzheimer's

    AAO '24: Real-world PDR Treatment vs. Protocol S Guidelines, and Retinal Imaging for Alzheimer's
    Dec 5 2024
    How many real-world patients with proliferative DR were concordant with the treatment directions in Protocol S? Adrienne Scott, MD, explains how a database review of real-world patients with proliferative DR revealed how few patients are concordant with the strict dosing schedule of Protocol S, and shares which baseline factors were linked to lack of concordance. And Dilraj Grewal, MD, provides an update on the relationship between retinal imaging and detection of Alzheimer disease. Just how close are we from using noninvasive retinal imaging techniques to screen for potential neurodegenerative conditions?
    Show more Show less
    32 mins
  • New Retina Radio Journal Club w/ VBS: Does Metformin Reduce AMD Risk?

    New Retina Radio Journal Club w/ VBS: Does Metformin Reduce AMD Risk?
    Nov 21 2024
    Does metformin use reduce the risk of developing AMD in non-diabetic patients? Moderator Rebecca Soares, MD, and panelists Matt Starr, MD, and Nikisha Kothari, MD, review a decade-long case control-control study assessing risk of AMD in non-diabetic patients who have been taking metformin for any reason. They ask whether the study's blindspots undercut its findings, and speculate what other questions further research could answer.
    Show more Show less
    15 mins
  • AAO '24 Late-Breakers: Preventing Fas Activation Prior to RRD Repair, and Phase 2/3 Data on an Oral Therapy for GA

    AAO '24 Late-Breakers: Preventing Fas Activation Prior to RRD Repair, and Phase 2/3 Data on an Oral Therapy for GA
    Nov 14 2024
    We’ve got to keep our eye on the pipeline. What do the latest data tell us about two drug candidates? Durga Borkar, MD, MMCi, reviews data from a phase 2 study assessing the safety and efficacy ONL1204 (ONL Therapeutics) delivered prior to RRD surgery. Did injecting ONL1204, which prevents Fas activation, lead to any postsurgical differences? Alex Melamud stops by to discuss the phase 2/3 SAGA study assessing the safety and efficacy of gildeuretinol (Alkeus Pharmaceuticals), an oral agent for the treatment of geographic atrophy. Can this drug succeed where other oral options in retina have failed?
    Show more Show less
    20 mins
  • AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMD

    AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMD
    Nov 7 2024
    The ELEVATUM study exclusively enrolled historically underrepresented patients in a study assessing faricimab (Vabysmo, Genentech/Roche) for DME. Were there any surprises in the data? Jeremiah Brown, MD, MS, sits down with New Retina Radio to review the philosophy behind the ELEVATUM study, discuss the study’s findings, and preview the next phases of the trial. And Eric Schneider, MD, joins the program to discuss the findings of a pivotal study assessing home OCT (Scanly, Notal Vision) in wet AMD patients. Is home OCT equivalent to in-office OCT when it comes to visualization? And do expert graders agree with an AI algorithm’s assessments of patient’s pathology?
    Show more Show less
    25 mins